**MINUTES**

**CPIC CONFERENCE CALL**

DATE: June 7, 2018

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress | Guideline updates in progress:   * *TPMT/NUDT15/*thiopurines*:* sending out for CPIC review (see below) * *CYP2C9/HLA/*phenytoin: In evidence review   New guidelines in progress:   * *RYR1*/inhaled anesthetics: sent out for CPIC review (comments/edit due **June 21st**)-send to Kelly * *CYP2B6*/efavirenz: Recommendation drafted; Drafting guideline * *CYP2D6/*atomoxetine: Evidence review complete; drafting recommendation * *CYP2C19/*PPI: Evidence review underway * *CYP2C9/*celecoxib: Evidence review underway | Guideline preparation will continue and Kelly will continue to follow-up. |
| Thiopurine guideline | The CPIC guideline for TPMT and NUDT15 and thiopurine dosing was presented on the call, specifically Tables 1 and 2. Members discussed. Kelly will send out guideline and supplemental tables for CPIC review with minutes. | Send any comments/edits to Kelly by **June 25th**. |
| Codeine use in children-FDA citizen petition open for comment | A group led by Roseann Gammal and Kristen Crews drafted a citizen’s petition regarding the recent contraindication of codeine in children less than 12. The petition requests a change to the contraindication “Codeine should not be used to treat pain or cough in children younger than 12 years” to “Codeine should not be used to treat pain or cough in children younger than 12 years with the following exception: Outside the setting of post-tonsillectomy or adenoidectomy, codeine may be prescribed for pain management in children younger than 12 years old who are known  CYP2D6 normal metabolizers (NMs) or CYP2D6 intermediate metabolizers (IMs) based on pharmacogenetic testing that includes CYP2D6 copy number or gene duplication detection.” The petition outlines eight rationales for this change. The petition is currently available for comment: <https://www.regulations.gov/docket?D=FDA-2017-P-6918> due June 18th. We expect to hear a decision from the FDA shortly after this date. | If you would like to comment, please do so before the deadline **June 18th**. |
| CPIC guideline dissemination working group | CPIC is forming a Guideline Dissemination Working Group to strategize on how to create clinician awareness and general understanding of CPIC guidelines. If you are interested in joining this group, please fill out this doodle poll: [https://doodle.com/poll/wmmh2k8zsagke6zw](https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoodle.com%2Fpoll%2Fwmmh2k8zsagke6zw&data=01%7C01%7Ckelly.caudle%40stjude.org%7Ce124730c0cc64c9e386d08d5cc93f946%7C22340fa892264871b677d3b3e377af72%7C0&sdata=6Yhcn3GlItjUX1AqoUyViBadRDtvTOVyu6vvPEKZvUQ%3D&reserved=0). | Kelly will continue to follow-up. |
| Mt-RNR1/aminoglycosides | William Newman presented about the mitochondrial variant Mt-*RNR1* and the association with aminoglycoside-induced ototoxicity. Slides posted with these minutes. | n/a |